CLC number:
On-line Access: 2022-06-08
Received: 2022-01-27
Revision Accepted: 2022-04-01
Crosschecked: 2022-06-08
Cited: 0
Clicked: 3024
Gang WANG, Ze XIANG, Wei WANG, Zhi CHEN. Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2200049 @article{title="Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic", %0 Journal Article TY - JOUR
季节性冠状病毒和SARS-CoV-2:在COVID-19疫情中预存免疫的影响1浙江大学医学院附属第一医院传染病诊治国家重点实验室、国家感染性疾病临床医学研究中心、国家传染病医学中心、感染性疾病诊治协同创新中心,中国杭州市,310003 2浙江大学医学院,中国杭州市,310003 3江苏省寄生虫病研究所,中国无锡市,214064 摘要:新型冠状病毒肺炎(COVID-19)疫情仍在持续,疫苗接种率正在缓慢上升,相关治疗方法和药物也在研发中。越来越多的证据表明,人类群体中已存在针对严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)的免疫力,包括抗体和免疫细胞(T细胞和B细胞)。这些抗体的存在主要是由于四种常见冠状病毒类型(尤其OC43和HKU1)的季节性流行所致。预存抗体的靶点主要是S蛋白的S2亚基,其次是核衣壳(N)等蛋白进化保守区。此外,人群中也存在预存的记忆T细胞和B细胞。预存抗体可以帮助身体抵御SARS-CoV-2感染,降低COVID-19的严重程度并迅速增加感染后的免疫反应。这些多重影响可以直接影响某些个体的疾病进展,甚至死亡的风险性。除了积极作用外,预存免疫也可能产生消极后果,例如抗体依赖性增强(ADE)和原始抗原原罪(OAS),其流行程度需要进一步确定。未来,更多的研究应侧重于评估已有免疫力在COVID-19中的作用,采取适当的政策和策略来抗击新冠大流行,同时也要考虑已有免疫力的疫苗开发。 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]AndersonEM, GoodwinEC, VermaA, et al., 2021. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell, 184(7):1858-1864.e10. [2]BonifaciusA, Tischer-ZimmermannS, DragonAC, et al., 2021. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity, 54(2):340-354.e6. [3]BraunJ, LoyalL, FrentschM, et al., 2020. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 587(7833):270-274. [4]CaoWC, LiuW, ZhangPH, et al., 2007. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med, 357(11):1162-1163. [5]DaiLP, GaoGF, 2021. Viral targets for vaccines against COVID-19. Nat Rev Immunol, 21(2):73-82. [6]de AssisRR, JainA, NakajimaR, et al., 2021. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. Nat Commun, 12:6. [7]de VriesRD, 2020. SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity. Signal Transduct Tar Ther, 5:224. [8]DongES, DuHR, GardnerL, 2020. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis, 20(5):533-534. [9]DoshiP, 2020. Covid-19: do many people have pre-existing immunity? BMJ, 370:m3563. [10]FengBH, ZhangD, WangQ, et al., 2021. Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(4):330-340. [11]FierzW, WalzB, 2020. Antibody dependent enhancement due to original antigenic sin and the development of SARS. Front Immunol, 11:1120. [12]GreenbaumJA, KotturiMF, KimY, et al., 2009. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA, 106(48):20365-20370. [13]GrifoniA, WeiskopfD, RamirezSI, et al., 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 181(7):1489-1501.e15. [14]HuangCL, WangYM, LiXW, et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223):497-506. [15]HuangY, YangC, XuXF, et al., 2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin, 41(9):1141-1149. [16]JacksonCB, FarzanM, ChenB, et al., 2022. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol, 23(1):3-20. [17]JiaLQ, WengSF, WuJ, et al., 2022. Pre-existing antibodies targeting a linear epitope on SARS-CoV-2 S2 cross-reacted with commensal gut bacteria and shaped vaccine induced immunity. medRxiv, prepint. [18]KaplonekP, WangCQ, BartschY, et al., 2021. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv, prepint. [19]KingAMQ, AdamsMJ, CarstensEB, et al., 2011. Virus Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier, St. Louis, p.770-783. [20]KisslerSM, TedijantoC, GoldsteinE, et al., 2020. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science, 368(6493):860-868. [21]KnoopsK, KikkertM, van den WormSHE, et al., 2008. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol, 6(9):e226. [22]KupferschmidtK, 2021. New coronavirus variants could cause more reinfections, require updated vaccines. Science COVID-19 Report. https://www.science.org/content/article/new-coronavirus-variants-could-cause-more-reinfections-require-updated-vaccines [accessed on Jan. 15, 2021]. [23]LappSA, EdaraVV, LuA, et al., 2021. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. PLoS ONE, 16(8):e0256482. [24]LauringAS, MalaniPN, 2021. Variants of SARS-CoV-2. JAMA, 326(9):880-880. [25]le BertN, TanAT, KunasegaranK, et al., 2020. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 584(7821):457-462. [26]LeeWS, WheatleyAK, KentSJ, et al., 2020. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol, 5(10):1185-1191. [27]LefkowitzEJ, DempseyDM, HendricksonRC, et al., 2018. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucl Acids Res, 46(D1):D708-D717. [28]MajdoubiA, MichalskiC, O'ConnellSE, et al., 2021. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. JCI Insight, 6(8):e146316. [29]MilletJK, JaimesJA, WhittakerGR, 2021. Molecular diversity of coronavirus host cell entry receptors. FEMS Microbiol Rev, 45(3):fuaa057. [30]Mveang NzogheA, EssonePN, LebouenyM, et al., 2021. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2. Immun, Inflamm Dis, 9(1):128-133. [31]NeteaMG, JoostenLAB, LatzE, et al., 2016. Trained immunity: a program of innate immune memory in health and disease. Science, 352(6284):aaf1098. [32]NgKW, FaulknerN, CornishGH, et al., 2020. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science, 370(6522):1339-1343. [33]NgOW, ChiaA, TanAT, et al., 2016. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine, 34(17):2008-2014. [34]Nguyen-ContantP, EmbongAK, KanagaiahP, et al., 2020. S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio, 11(5):e01991-20. [35]OrtegaN, RibesM, VidalM, et al., 2021. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun, 12:4740. [36]SchulienI, KemmingJ, OberhardtV, et al., 2021. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat Med, 27(1):78-85. [37]SetteA, CrottyS, 2020. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol, 20(8):457-458. [38]ShiY, WangG, CaiXP, et al., 2020. An overview of COVID-19. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(5):343-360. [39]SongG, HeWT, CallaghanS, et al., 2021. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun, 12:2938. [40]SridharS, BegomS, BerminghamA, et al., 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med, 19(10):1305-1312. [41]SuiZW, DaiXH, LuQB, et al., 2021. Viral dynamics and antibody responses in people with asymptomatic SARS-CoV-2 infection. Signal Transduct Tar Ther, 6:181. [42]VashishthaVM, 2021. Is ‘original antigenic sin’ complicating Indian vaccination drive against Covid-19? Hum Vacc Immunother, 17(10):3314-3315. [43]WeiskopfD, SchmitzKS, RaadsenMP, et al., 2020. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol, 5(48):eabd2071. [44]WilkinsonTM, LiCKF, ChuiCSC, et al., 2012. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med, 18(2):274-280. [45]WuF, ZhaoS, YuB, et al., 2020. A new coronavirus associated with human respiratory disease in China. Nature, 579(7798):265-269. [46]ZhouP, YangXL, WangXG, et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798):270-273. Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>